Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
Authors
Keywords
Melanoma, CTLA4, Ipilimumab, Regulatory T cells, MDSC, Tumor antigens
Journal
Journal of Translational Medicine
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-07-04
DOI
10.1186/s12967-018-1563-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Therapy for Melanoma
- (2017) Aya Agha et al. Current Oncology Reports
- CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.
- (2017) A. Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
- (2014) Yago Pico de Coaña et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Increased frequencies of CD11b+CD33+CD14+HLA-DRlowmyeloid-derived suppressor cells are an early event in melanoma patients
- (2014) Berenice M. Rudolph et al. EXPERIMENTAL DERMATOLOGY
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients
- (2013) Kimberly R. Jordan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
- (2013) Y. P. de Coana et al. Cancer Immunology Research
- Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
- (2012) A. Gros et al. CLINICAL CANCER RESEARCH
- Phenotypic and functional characteristics of CD4+CD39+ FOXP3+ and CD4+CD39+FOXP3neg T-cell subsets in cancer patients
- (2012) Patrick J. Schuler et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
- (2012) Ahmad A. Tarhini et al. JOURNAL OF IMMUNOTHERAPY
- Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen
- (2012) Stefano Ugel et al. Cell Reports
- A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
- (2011) S. Solito et al. BLOOD
- Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
- (2011) Paola Filipazzi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets
- (2011) Patrick J. Schuler et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
- (2010) Isabel Poschke et al. CANCER RESEARCH
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity
- (2010) Je-In Youn et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression
- (2009) Magis Mandapathil et al. JOURNAL OF IMMUNOLOGICAL METHODS
- No Correlation Between Clinical Response to CTLA-4 Blockade and Presence of NY-ESO-1 Antibody in Patients With Metastatic Melanoma
- (2009) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
- (2008) C. Menard et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started